Peloton Therapeutics, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: Dallas TX United States (2010)
Status: Acquired by Merck (2019)

Organization Overview

First Clinical Trial
2014
NCT02293980
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Peloton Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

Belzutifan (Welireg) (4 trials)

cabozantinib (cometriq) (2 trials)

pt2385 (3 trials)

Drugs in Phase 1 Trials (1)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Adenocarcinoma, Clear Cell (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Glioblastoma (Phase 1)

Kidney Neoplasms (Phase 2)

Neoplasms (Phase 1)

Syndrome (Phase 2)

von Hippel-Lindau Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4